Lymphoma

1st line         STAR study
Seattle Genetics SGN-35-015      (USOR 11282) Kong
Phase II
Brentuximab vedotin
Hodgkin’s Lymphoma, age >59, ineligible for or declined standard Rx

 

2nd+ line
GSK OFB114612
(USOR 10255) Kelley
Phase II
Arzerra + Treanda followed by maintenance Arzerra
Relapsed, Rituxan-sensitive (>6 months response), indolent, CD20+ lymphomas.

 

2nd + line         STAR study
Seattle Genetics SGN-35-012      (USOR 11262) Kong
Phase II
Brentuximab vedotin
Relapsed or refractory CD30+ DLBCL or T-cell NHL

PHONE (805) 485-8709

FAX (805-485-5521

  • LinkedIn Social Icon
  • Yelp Social Icon
  • Facebook Social Icon

Oxnard Office: 1700 North Rose Ave Suite 320, Oxnard, CA  93030

Ventura Office: 2900 Loma Vista Road Suite 200, Ventura, CA  93003
Camarillo Office: 500 Paseo Camarillo Suite 106, Camarillo, CA 93010

Copyright ©2002-2020

Ventura County Hematology Oncology Specialists